---
title: "From year-end, the D2T RA approval direction will be discussed with the FDA, and GD (Phase 2b) and… — 하나증권 제약/바이오 김선아 — DecisionGateway"
description: "commitment by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492"
meta:
  "og:description": "commitment by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "From year-end, the D2T RA approval direction will be discussed with the FDA, and GD (Phase 2b) and… — 하나증권 제약/바이오 김선아 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

commitment

# **From year-end, the D2T RA approval direction will be discussed with the FDA, and GD (Phase 2b) and MG (Phase 3) top-line results are scheduled for 2027.**

A commitment by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *연말부터 D2T RA 허가 방향을 FDA와 협의하고, ‘27년 GD(2b상)와 MG(3상) 탑라인 발표 예정*

hanaresearchPublished 2026-11-10 [ Read source](https://t.me/hanaresearch/20929)

## **Discussion**

## **Related claims**

[**In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6d1-7aec-8105-c4689a803513) [**Topline data from the Graves' disease (GD) Phase 2b and myasthenia gravis (MG) Phase 3 registrational trials are expected in 2027.**report author · prediction](https://dgw.tmarket.io/claims/01a1d4b6-f70a-7976-b000-2e65792a1965) [**Following the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6fe-7e21-bace-a811a7b3596d) [**In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved a p-value.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-398b-7bf3-a65b-cf8bdaaf0349) [**在2026年10月13日或之后提交的申请将不会被受理，直至另行通知。**汇丰香港 · prediction](https://dgw.tmarket.io/claims/01a1d5e3-8e58-7445-9047-23ac0007964b) [**Coverage initiated with a target price of 80,000 won, expecting MG and GD clinical results in 2027.**하나증권 제약/바이오 김선아 · commitment](https://dgw.tmarket.io/claims/01a1d887-39d6-7025-b897-501eb5b9aeea)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492#webpage","@type":"WebPage","description":"commitment by 하나증권 제약/바이오 김선아, recorded recently — verbatim quote and source citation.","name":"From year-end, the D2T RA approval direction will be discussed with the FDA, and GD (Phase 2b) and… — 하나증권 제약/바이오 김선아 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"From year-end, the D2T RA approval direction will be…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d887-39ef-7f11-b86c-add32205f492#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/hanaresearch/20929","text":"연말부터 D2T RA 허가 방향을 FDA와 협의하고, ‘27년 GD(2b상)와 MG(3상) 탑라인 발표 예정","url":"/claims/01a1d887-39ef-7f11-b86c-add32205f492"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.